These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 7959407)

  • 41. 5-HT3 receptor-independent inhibition of the depolarization-induced 86Rb efflux from human neuroblastoma cells, TE671, by ondansetron.
    Toral J; Hu W; Critchett D; Solomon AJ; Barrett JE; Sokol PT; Ziai MR
    J Pharm Pharmacol; 1995 Jul; 47(7):618-22. PubMed ID: 8568632
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.
    Simpson K; Spencer CM; McClellan KJ
    Drugs; 2000 Jun; 59(6):1297-315. PubMed ID: 10882164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis.
    Lindley C; Blower P
    Am J Health Syst Pharm; 2000 Sep; 57(18):1685-97. PubMed ID: 11006796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 5-HT3 receptor antagonists and migraine therapy.
    Ferrari MD
    J Neurol; 1991; 238 Suppl 1():S53-6. PubMed ID: 2045832
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanism of action of 5-HT3 receptor antagonists: clinical overview and nursing implications.
    Bremerkamp M
    Clin J Oncol Nurs; 2000; 4(5):201-7. PubMed ID: 11111451
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The neuronal 5-HT3 receptor network after 20 years of research--evolving concepts in management of pain and inflammation.
    Faerber L; Drechsler S; Ladenburger S; Gschaidmeier H; Fischer W
    Eur J Pharmacol; 2007 Mar; 560(1):1-8. PubMed ID: 17316606
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
    Tsukagoshi S; Ohta J; Taguchi T
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2276-81. PubMed ID: 8259839
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment.
    Aapro M
    Oncology; 2005; 69(2):97-109. PubMed ID: 16131816
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban).
    Morrow GR; Hickok JT; Rosenthal SN
    Cancer; 1995 Aug; 76(3):343-57. PubMed ID: 8625113
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Studies on serotonin (5-HT)3-receptor antagonist effects of enantiomers of 4,5,6,7-tetrahydro-1H-benzimidazole derivatives.
    Kamato T; Ito H; Suzuki T; Miyata K; Honda K
    Jpn J Pharmacol; 1995 Mar; 67(3):185-94. PubMed ID: 7630036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemical modulation of 5-HT3 and 5-HT4 receptors affects the release of 5-hydroxytryptamine from the ferret and rat intestine.
    Minami M; Tamakai H; Ogawa T; Endo T; Hamaue N; Hirafuji M; Yoshioka M; Blower PR
    Res Commun Mol Pathol Pharmacol; 1995 Aug; 89(2):131-42. PubMed ID: 8556268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine.
    Gebauer A; Merger M; Kilbinger H
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Feb; 347(2):137-40. PubMed ID: 8474534
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SR 57227A: a potent and selective agonist at central and peripheral 5-HT3 receptors in vitro and in vivo.
    Bachy A; Héaulme M; Giudice A; Michaud JC; Lefevre IA; Souilhac J; Manara L; Emerit MB; Gozlan H; Hamon M
    Eur J Pharmacol; 1993 Jun; 237(2-3):299-309. PubMed ID: 7689975
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of 5-hydroxytryptamine- and enterotoxin-induced fluid secretion by 5-HT receptor antagonists in the rat jejunum.
    Beubler E; Schirgi-Degen A; Gamse R
    Eur J Pharmacol; 1993 Aug; 248(2):157-62. PubMed ID: 8223962
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The involvement of 5-HT3 and 5-HT4 receptors in two models of gastrointestinal transit in mice.
    Pascual D; Alsasua A; Goicoechea C; Martín MI
    Neurosci Lett; 2002 Jul; 326(3):163-6. PubMed ID: 12095647
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
    Gridelli C
    Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.
    Wong EH; Clark R; Leung E; Loury D; Bonhaus DW; Jakeman L; Parnes H; Whiting RL; Eglen RM
    Br J Pharmacol; 1995 Feb; 114(4):851-9. PubMed ID: 7773546
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drugs acting on serotonin receptors for the treatment of functional GI disorders.
    Tonini M; Pace F
    Dig Dis; 2006; 24(1-2):59-69. PubMed ID: 16699264
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The function of 5-HT3 receptors on colonic transit in rats.
    Haga K; Asano K; Fukuda T; Kobayakawa T
    Obes Res; 1995 Dec; 3 Suppl 5():801S-810S. PubMed ID: 8653566
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mediation by 5-HT3 receptors of an excitatory effect of 5-HT on dorsal vagal preganglionic neurones in anaesthetized rats: an ionophoretic study.
    Wang Y; Ramage AG; Jordan D
    Br J Pharmacol; 1996 Aug; 118(7):1697-704. PubMed ID: 8842434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.